坚持CD19。CAR-T细胞联合尼达尼布：2年后系统性硬化症相关肺纤维化患者的临床反应

IF 38.7 1区医学 Q1 CRITICAL CARE MEDICINE

Lancet Respiratory Medicine Pub Date : 2025-05-28 DOI:10.1016/s2213-2600(25)00159-6

Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou, Ayla Nadja Stütz, Jörg H W Distler, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin Lorenz

{"title":"坚持CD19。CAR-T细胞联合尼达尼布：2年后系统性硬化症相关肺纤维化患者的临床反应","authors":"Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou, Ayla Nadja Stütz, Jörg H W Distler, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin Lorenz","doi":"10.1016/s2213-2600(25)00159-6","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>WM and H-ML oversaw the project; MR and EM were involved with FAPI-PET/CT, including graphs; CPH was involved with CT-imaging, including graphs; WM, H-ML, AS, JHWD, and MP were responsible for clinical data interpretation; WM, MS, AS, H-ML, and MP cared for the patient; WM was responsible for data handling; WM and ANS wrote the manuscript; and all authors critically reviewed the manuscript and had final responsibility for the decision to submit for publication. We thank all staff of the</section></section><section><section><h2>Declaration of interests</h2>WM has received grants or contracts from the German Society of Internal Medicine (DGIM), ArgenX, Kyverna, Eli Lilly, Galapagos, Boehringer Ingelheim, Evotec, and Bristol Myers Squibb; consulting fees and payment or honoraria for lectures and presentations from Eli Lilly, Galapagos, and Boehringer Ingelheim; support for attending meetings, travel, or both from Kyverna, Eli Lilly, Galapagos, and Boehringer Ingelheim; has patents planned with Evotec and Bristol Myers Squibb; has participated on an</section></section>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"73 1","pages":""},"PeriodicalIF":38.7000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years\",\"authors\":\"Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou, Ayla Nadja Stütz, Jörg H W Distler, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin Lorenz\",\"doi\":\"10.1016/s2213-2600(25)00159-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Contributors</h2>WM and H-ML oversaw the project; MR and EM were involved with FAPI-PET/CT, including graphs; CPH was involved with CT-imaging, including graphs; WM, H-ML, AS, JHWD, and MP were responsible for clinical data interpretation; WM, MS, AS, H-ML, and MP cared for the patient; WM was responsible for data handling; WM and ANS wrote the manuscript; and all authors critically reviewed the manuscript and had final responsibility for the decision to submit for publication. We thank all staff of the</section></section><section><section><h2>Declaration of interests</h2>WM has received grants or contracts from the German Society of Internal Medicine (DGIM), ArgenX, Kyverna, Eli Lilly, Galapagos, Boehringer Ingelheim, Evotec, and Bristol Myers Squibb; consulting fees and payment or honoraria for lectures and presentations from Eli Lilly, Galapagos, and Boehringer Ingelheim; support for attending meetings, travel, or both from Kyverna, Eli Lilly, Galapagos, and Boehringer Ingelheim; has patents planned with Evotec and Bristol Myers Squibb; has participated on an</section></section>\",\"PeriodicalId\":51307,\"journal\":{\"name\":\"Lancet Respiratory Medicine\",\"volume\":\"73 1\",\"pages\":\"\"},\"PeriodicalIF\":38.7000,\"publicationDate\":\"2025-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2213-2600(25)00159-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00159-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

贡献者swm和H-ML监督项目；MR、EM涉及FAPI-PET/CT，包括图；CPH涉及ct成像，包括图表；WM、H-ML、AS、JHWD、MP负责临床资料解释；WM、MS、AS、H-ML、MP对患者进行护理；WM负责数据处理；WM和ANS撰写了手稿；所有作者都对稿件进行了严格的审查，并对是否发表的决定负有最终责任。我们感谢利益声明的所有工作人员，swm已获得来自德国内科学会（DGIM）、ArgenX、Kyverna、礼来、Galapagos、勃林格殷格翰、Evotec和Bristol Myers Squibb的资助或合同；来自礼来、加拉帕戈斯和勃林格殷格翰的讲座和演讲的咨询费和报酬或酬金；支持参加来自Kyverna、礼来、加拉帕戈斯和勃林格殷格翰的会议、旅行或两者兼而有之；拥有Evotec和Bristol Myers Squibb的专利计划；曾参加过

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years

Section snippets

Contributors

WM and H-ML oversaw the project; MR and EM were involved with FAPI-PET/CT, including graphs; CPH was involved with CT-imaging, including graphs; WM, H-ML, AS, JHWD, and MP were responsible for clinical data interpretation; WM, MS, AS, H-ML, and MP cared for the patient; WM was responsible for data handling; WM and ANS wrote the manuscript; and all authors critically reviewed the manuscript and had final responsibility for the decision to submit for publication. We thank all staff of the

Declaration of interests

WM has received grants or contracts from the German Society of Internal Medicine (DGIM), ArgenX, Kyverna, Eli Lilly, Galapagos, Boehringer Ingelheim, Evotec, and Bristol Myers Squibb; consulting fees and payment or honoraria for lectures and presentations from Eli Lilly, Galapagos, and Boehringer Ingelheim; support for attending meetings, travel, or both from Kyverna, Eli Lilly, Galapagos, and Boehringer Ingelheim; has patents planned with Evotec and Bristol Myers Squibb; has participated on an

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM

CiteScore

87.10

自引率

0.70%

发文量

572

期刊介绍： The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.